Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chuang, Y.-C.
Right arrow Articles by Kuo, C.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chuang, Y.-C.
Right arrow Articles by Kuo, C.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 947-954
© 2003 European Renal Association-European Dialysis and Transplant Association

Significance of platelet activation in vascular access survival of haemodialysis patients

Yao-Cheng Chuang1,, Jin-Bor Chen1, Lin-Cheng Yang3 and Ching-Yuan Kuo2

1 Division of Nephrology, 2 Division of Hematology, Department of Internal Medicine and 3 Second Department of Anesthesiology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China

Background. Vascular access failure is the most common cause of morbidity and hospitalization in haemodialysis (HD) patients. Although there are reports that anti-platelet agents can prevent vascular access thrombosis, the relationship between platelet activation and vascular access failure is not clear. The aim of this study was to investigate the role of platelet activation in recurrent vascular access failure.

Methods. The studied subjects were divided into three groups: group I included 23 HD patients with recurrent vascular access failure (native arteriovenous fistula <2 year survival or synthetic arteriovenous graft <1 year survival), group II included 15 HD patients with longer vascular access survival (>5 year survival) and group III included 10 healthy volunteers as controls. The expression of platelet activation markers (CD62P and fibrinogen receptor) and the numbers of platelet-derived microparticles were measured and compared between groups.

Results. CD62P-positive platelets were significantly higher in group I than in both group II (7.3±3.7 vs 3.5±1.3%; P<0.0005) and group III (2.9±0.9%; P<0.00005). Fibrinogen receptor-positive (PAC-1-positive) platelets were also significantly higher in group I than in group II (2.2±2.1 vs 0.9±0.7%; P<0.01) and group III (0.8±0.6%; P<0.01).

Conclusions. A higher level of circulating activated platelets is associated with shorter survival of vascular access in HD patients. The higher level of circulating activated platelets may be a predictor of recurrent vascular access failure. The potential advantageous effects of anti-platelet therapy on this patient population warrant further investigation.

Keywords: CD62P; haemodialysis; PAC-1; platelet activation; platelet-derived microparticles; vascular access survival

Correspondence and offprint requests to: Yao-Cheng Chuang, MD, Division of Nephrology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung Hsien, Taiwan 833, Republic of China. Email: mdchuang{at}giga.net.tw


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.